| Size | Price | Stock | Qty |
|---|---|---|---|
| 250g |
|
||
| 500g |
|
||
| Other Sizes |
| Targets |
2-Methoxycinnamic acid targets tyrosinase, the key enzyme in melanin biosynthesis. It is a noncompetitive inhibitor of tyrosinase. By inhibiting tyrosinase, the compound reduces melanin production. It also functions as a Brassica napus metabolite.
|
|---|---|
| ln Vitro |
2-Methoxycinnamic acid demonstrates potent in vitro tyrosinase inhibitory activity. It is a noncompetitive inhibitor of tyrosinase. The compound effectively reduces melanin production in vitro. It has been identified as a tyrosinase inhibitor from Pulsatilla cernua root-derived materials.
|
| ln Vivo |
In vivo activity data for 2-Methoxycinnamic acid are not extensively documented. Its ability to inhibit tyrosinase and reduce melanin production suggests potential in vivo efficacy for skin lightening. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
The in vitro enzyme assay for 2-Methoxycinnamic acid involves measuring its inhibition of tyrosinase activity. Mushroom tyrosinase is commonly used as a model enzyme. The assay typically uses L-DOPA as a substrate, and the formation of dopachrome is monitored spectrophotometrically at 475 nm. 2-Methoxycinnamic acid is incubated with the enzyme and substrate at various concentrations. The IC50 value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for 2-Methoxycinnamic acid typically use B16 melanoma cells or human melanocytes to assess its effects on melanogenesis. Cells are treated with the compound at various concentrations. Melanin content is measured spectrophotometrically. Tyrosinase activity is assessed by measuring the oxidation of L-DOPA in cell lysates. The compound's ability to reduce melanin production is quantified.
|
| Animal Protocol |
In vivo animal experiments for 2-Methoxycinnamic acid are not extensively documented. As a tyrosinase inhibitor, standard in vivo studies would involve animal models of hyperpigmentation. The compound would be administered via topical or oral routes. Melanin content in skin and histopathological analysis would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Methoxycinnamic acid are not extensively documented. As a small molecule with a molecular weight of 178.18, the compound is expected to have reasonable bioavailability. Its cinnamic acid structure may influence its absorption, distribution, metabolism, and excretion. Further pharmacokinetic studies are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-Methoxycinnamic acid are not extensively available. As a naturally occurring compound, it is generally considered to have a favorable safety profile. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further toxicological studies would be required for clinical development.
|
| References | |
| Additional Infomation |
(E)-2-Methoxycinnamic acid is a cinnamic acid compound, specifically trans-cinnamic acid with a methoxy substituent at the 2-position of the benzene ring. It is a metabolite of Brassica napus and an inhibitor of tyrosinase (EC 1.14.18.1). It belongs to the cinnamic acid class and is a monomethoxybenzene compound. Functionally, it is related to trans-cinnamic acid.
See also: Cinnamomum cassia branches (partial). 2-Methoxycinnamic acid is a noncompetitive inhibitor of tyrosinase found in plants such as Pulsatilla cernua. It reduces melanin production and is used in research on pigmentation disorders and skin whitening. The compound has a molecular weight of 178.18. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C10H10O3
|
|---|---|
| Molecular Weight |
178.18
|
| Exact Mass |
178.062
|
| CAS # |
6099-03-2
|
| PubChem CID |
734154
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
325.1±17.0 °C at 760 mmHg
|
| Melting Point |
182-186 °C
|
| Flash Point |
130.3±14.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
2.42
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
198
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC=C1/C=C/C(=O)O
|
| InChi Key |
FEGVSPGUHMGGBO-VOTSOKGWSA-N
|
| InChi Code |
InChI=1S/C10H10O3/c1-13-9-5-3-2-4-8(9)6-7-10(11)12/h2-7H,1H3,(H,11,12)/b7-6+
|
| Chemical Name |
(E)-3-(2-methoxyphenyl)prop-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (561.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6123 mL | 28.0615 mL | 56.1230 mL | |
| 5 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL | |
| 10 mM | 0.5612 mL | 2.8062 mL | 5.6123 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
